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ABSTRACT 
Staphylococcus aureus is a major cause of bloodstream infections and endocarditis. S. aureus 
bacteraemia (SAB) is associated with substantial morbidity and mortality, and endocarditis is 
a severe complication. Population-based studies on S. aureus bacteraemia have been sparse, 
and few large studies exist on S. aureus endocarditis (SAE).  
The objective of this thesis was to study the epidemiology, characteristics, and short- and 
long-term outcome of S. aureus bacteraemia and endocarditis in Iceland and Stockholm. 
In paper I and II we studied SAB in the entire Icelandic adult and paediatric populations. 
Cases were retrospectively identified at the clinical microbiological laboratories.  
In adults the incidence was 24.5 /100,000 person-years during 1995-2008 (721 cases), 
increasing by 28% during the study period (p=0.01). The paediatric incidence was 10.9 
/100,000 child-years during 1995-2011 (146 cases), decreasing by 36% during the period 
(p=0.001). At the same time the average annual frequency of blood cultures from children 
analysed at the main study site decreased by 27% (p<0.001). SAB incidence was highest in 
infants (<1 year), 58.8 /100,000.  
The proportion of adults with nosocomial infections decreased from 56% in 1995-99 to 39% 
in 2005-08 (p=0.001), while community acquired SAB increased from 29% to 46% 
(p<0.001). Health-care associated community-onset cases were 15%. Among the paediatric 
cases 34% were nosocomial, 14% health-care associated, and 51% community acquired. 
Bone or joint infection was the focus of SAB in 40% of children, followed by intravascular 
catheters in 30%, and an unknown focus in 10%.  
The 30-day mortality in adults was 17.1%, and decreased from 22.2% during 1995-99 to 
11.4% during 2005-08 (p=0.001). The 1-year mortality was 33.0%, and decreased from 
38.9% to 28.2% (p=0.06). In children the SAB-related mortality was 0.7%, 30-day mortality 
1.4%, and the 1-year mortality 3.6%. These case fatality ratios are lower than those observed 
in most previous studies.  
In paper III we studied SAE in adults in Stockholm, and in paper IV we specifically 
focused on SAE in people who inject drugs. Individuals treated for SAE at the Department of 
Infectious Diseases at the Karolinska University Hospital were retrospectively identified by 
diagnostic codes from medical records.  
The calculated incidence of SAE in adults in Stockholm County was 1.56 /100,000 person-
years during 2004-13 (245 cases), and the incidence of SAE related to intravenous drug use 
(IVDU) was 0.76 /100,000 person-years (120 cases). This incidence is high in comparison 
with other regions. The SAE incidence increased by 42% during the study period (p=0.002), 
and this was largely caused by a change in the incidence of the IVDU-related SAE which 
increased by 91% (p=0.02). The SAE incidence among people who inject drugs in Stockholm 
was estimated to be 2.5 (range 1.5-6.5) per 1,000 person-years.  
Thirty-day, in-hospital, and 1-year mortality rates were 6.1%, 9.0%, and 19.7%, respectively, 
among all SAE cases. In-hospital and 1-year mortality rates associated with IVDU-related 
SAE were 2.5% and 8.0%, respectively. The case fatality ratios noted are very low compared 
to previous reports. Age and female sex were independently associated with in-hospital 
mortality in a multivariate analysis, and age and left-sided disease with the 1-year mortality. 
Central nervous system (CNS) involvement was observed in 12% of patients, and valvular 
surgery was performed during hospitalisation in 15%. In left-sided SAE the strongest 
predictors for surgery were lower age and not being an intravenous-drug-user, and for CNS 
involvement lower age.  
In conclusion, we found an increasing incidence of SAB and SAE in adults, probably related 
to a change in risk factors both for SAB and SAE, and possibly due to more liberal 
diagnostics. The decrease noted in SAB incidence in children was probably in part due to 
lower blood culture frequency and possibly a result of infection control measures introduced. 
The reason for the favourable short- and long-term outcomes associated with SAB and SAE 
in Iceland and Stockholm is not clear. It could be related to diagnosis of more early and mild 
cases, but other factors might also have contributed. 
  
  
LIST OF SCIENTIFIC PAPERS 
 
I. Asgeirsson H, Gudlaugsson O, Kristinsson KG, Heiddal S, Kristjansson M. 
Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing 
incidence and mortality. Clin Microbiol Infect 2011; 17(4):513-8. 
II. Asgeirsson H, Gudlaugsson O, Kristinsson KG, Vilbergsson GR, Heiddal S, 
Haraldsson A, Weiland O, Kristjansson M. Low mortality of 
Staphylococcus aureus bacteremia in Icelandic children - nationwide 
study on incidence and outcome. Pediatr Infect Dis J 2014; [Epub ahead of 
print]. 
III. Asgeirsson H, Thalme A, Kristjansson M, Weiland O. High incidence and 
low mortality in Staphylococcus aureus endocarditis – a 10-year 
experience. Submitted manuscript. 
IV. Asgeirsson H, Thalme A, Weiland O. Staphylococcus aureus endocarditis 
in people who inject drugs – low mortality but increasing incidence. In 
manuscript. 
 
  
RELATED PUBLICATIONS 
 
i.  Asgeirsson H, Kristjansson M, Kristinsson KG, Gudlaugsson O. 
Staphylococcus aureus bacteraemia – Nationwide assessment of treatment 
adequacy and outcome. J Infect 2011; 62(5):339-46. 
ii.  Asgeirsson H, Kristjansson M, Kristinsson KG, Gudlaugsson O. Clinical 
significance of Staphylococcus aureus bacteriuria in a nationwide study of 
adults with S. aureus bacteraemia. J Infect 2012; 64(1):41-6. 
  
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 History and basic microbiology of Staphylococcus aureus ................................. 1 
1.2 Colonisation and pathogenesis of S. aureus ......................................................... 1 
1.3 Infections caused by S. aureus .............................................................................. 2 
1.4 S. aureus bacteraemia ............................................................................................ 3 
1.4.1 Incidence .................................................................................................... 3 
1.4.2 Mode of acquisition................................................................................... 5 
1.4.3 Focus .......................................................................................................... 5 
1.5 Infective endocarditis ............................................................................................ 6 
1.5.1 History and incidence ................................................................................ 6 
1.5.2 Pathogenesis .............................................................................................. 6 
1.5.3 Diagnosis ................................................................................................... 7 
1.6 Outcome of S. aureus bacteraemia and endocarditis ........................................... 9 
1.7 Antibiotic treatment of S. aureus bacteraemia and endocarditis........................ 11 
1.8 Cardiac surgery for S. aureus endocarditis ......................................................... 12 
1.9 People who inject drugs ...................................................................................... 12 
1.9.1 Infectious complications ......................................................................... 12 
1.9.2 Incidence of endocarditis ........................................................................ 13 
2 Aims ............................................................................................................................... 15 
3 Materials and methods .................................................................................................. 17 
3.1 Paper I and II – S. aureus bacteraemia ............................................................... 17 
3.1.1 Study population ..................................................................................... 17 
3.1.2 Study protocol ......................................................................................... 17 
3.1.3 Definitions ............................................................................................... 18 
3.1.4 Statistical analysis ................................................................................... 19 
3.1.5 Ethical permits ......................................................................................... 20 
3.2 Paper III and IV – S. aureus endocarditis ........................................................... 21 
3.2.1 Study population ..................................................................................... 21 
3.2.2 Study protocol ......................................................................................... 21 
3.2.3 Definitions ............................................................................................... 22 
3.2.4 Statistical analysis ................................................................................... 23 
3.2.5 Ethical permits ......................................................................................... 23 
4 Results and discussions ................................................................................................. 25 
4.1 Paper I and II – S. aureus bacteraemia ............................................................... 25 
4.1.1 Patients..................................................................................................... 25 
4.1.2 Incidence .................................................................................................. 25 
4.1.3 Mortality .................................................................................................. 28 
4.1.4 Mode of acquisition................................................................................. 32 
4.1.5 Focus in children ..................................................................................... 33 
4.1.6 Antibiotic resistance ................................................................................ 35 
4.2 Paper III and IV – S. aureus endocarditis ........................................................... 36 
4.2.1 Patients .................................................................................................... 36 
4.2.2 Incidence ................................................................................................. 38 
4.2.3 Characteristics ......................................................................................... 40 
4.2.4 Mortality .................................................................................................. 43 
4.2.5 Central nervous system complications ................................................... 46 
4.2.6 Treatment ................................................................................................. 47 
5 Conclusions ................................................................................................................... 51 
6 Acknowledgements ....................................................................................................... 53 
7 References ..................................................................................................................... 55 
 
  
  
LIST OF ABBREVIATIONS 
CI Confidence interval 
CLSI Clinical and Laboratory Standards Institute 
CNS Central nervous system 
HACEK Haemophilus spp, Actinobacillus actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella corrodens, Kingella 
kingae 
HBV Hepatitis B virus 
HCA Health-care associated 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
ICD Implantable cardioverter defibrillator 
ICU Intensive care unit 
ID Infectious diseases 
IE Infective endocarditis 
IgG Immunoglobulin G 
IQR Interquartile range 
IV Intravenous 
IVDU Intravenous drug use 
MRSA Methicillin resistant Staphylococcus aureus 
MSSA Methicillin sensitive Staphylococcus aureus 
OR Odds ratio 
PBP Penicillin-binding protein 
PWID People who inject drugs 
SAB S. aureus bacteraemia 
SAE S. aureus endocarditis 
 
  
 1 
 
1 INTRODUCTION 
 
1.1 HISTORY AND BASIC MICROBIOLOGY OF STAPHYLOCOCCUS AUREUS 
In 1880 Sir Alexander Ogston first described staphylococcal disease and its role in abscess 
formation and sepsis [1, 2]. In the first half of the 20
th
 century Staphylococcus aureus 
bloodstream infections carried a mortality of over 80% [3]. Today, more than a century after 
its discovery, S. aureus remains an important human pathogen, which can cause severe 
morbidity and death.  
S. aureus belongs to the family of Staphylococcaceae. The name Staphylococcus derives 
from the Greek words “staphyle” (bunch of grapes) and “kokkos” (granule), since in 
microscopy the organisms appear as cocci in clusters. After Gram-staining the bacteria colour 
Gram-positive. Colonies of S. aureus have a golden pigmentation. Hence, the species name 
aureus, which is derived from the Latin word “aurum” (gold). An important biochemical 
feature when distinguishing S. aureus from many other staphylococcal species, is its positive 
result in the coagulase test [4]. 
 
1.2 COLONISATION AND PATHOGENESIS OF S. AUREUS 
S. aureus is often found as an asymptomatic coloniser on the skin and mucosal surfaces of 
humans. The anterior nares are considered to be the primary colonisation site, although the 
bacteria may also be found in other locations such as in the throat, perineum, on the skin, and 
in the intestine. Approximately 30-50% of healthy people carry S. aureus in their nose, and 
10-20% are persistently colonised [4-8]. Colonised persons readily contaminate their local 
environments, with their hands or by airborne droplets from the nose, and can transmit the 
bacteria to others [8]. The hands of health-care workers have been a major source of 
staphylococcal transmission in hospitals [9-11]. The biology of colonisation of the skin and 
mucosal linings is multifactorial and incompletely understood, but colonisation is believed to 
precede infection [8, 12, 13]. 
Infection can occur when a rupture of the skin or mucosal barrier allows the bacteria to gain 
access to and invade adjoining tissues. Certain underlying conditions can predispose 
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individuals to S. aureus infections, such as diabetes mellitus, haemodialysis dependence, 
intravenous drug abuse, and certain immune defects [8, 14]. The virulence of S. aureus is 
determined by multiple bacterial factors controlling attachment (e.g. teichoic acid, 
fibronectin-binding protein), invasion (e.g. proteases, haemolysins) and immune evasion (e.g. 
protein A, leukotoxins, superantigenic toxins). In addition S. aureus has the ability to form 
protective biofilms, e.g. on prosthetic materials and heart valves. Infection is thus a result of 
an interaction between the S. aureus and the host. The infection can spread locally, or 
possibly gain access to the bloodstream. Hence, staphylococcal infection ranges from being 
localised to disseminated, and from being mild to severe, and possibly fatal [4, 14-16]. 
 
1.3 INFECTIONS CAUSED BY S. AUREUS 
S. aureus can infect virtually any organ. S. aureus is a major cause of skin and soft tissue 
infections, bone and joint infections and endovascular infections. It is also an important but 
less common cause of respiratory tract infections and urinary tract infections. The presence of 
foreign material in the human body (e.g. intravascular catheter, suture material, urinary tract 
catheter, joint prosthesis, and cardiac valve prosthesis) increases the risk for infection. This 
seems to be a result of increased bacterial adherence to the fibronectin and fibrinogen coated 
surfaces of foreign material, whereas a lack of vascularisation impairs the influx of 
leukocytes. Skin and soft tissue infections are the most common clinical manifestation of S. 
aureus infections in all age groups. They are thought to account for approximately 90% of all 
infections caused by S. aureus. Haematogenous seeding can lead to various clinical 
manifestations, such as septic arthritis, osteomyelitis, epidural abscesses, and endocarditis. 
The condition when bacteria are found in the blood is called S. aureus bacteraemia (SAB) [4, 
17]. S. aureus is a major pathogen of bloodstream infections in all age groups, both in the 
community and hospital settings [18-22]. SAB is a severe form of S. aureus infection which 
may be complicated by metastatic infections, endocarditis and septic shock [4, 17].  
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1.4 S. AUREUS BACTERAEMIA 
1.4.1 Incidence 
Population-based studies have been proposed as the best way to assess the epidemiology of 
serious infectious diseases since all cases within a predefined geographical area are included. 
Nationwide studies further diminish the likelihood of selection and referral bias [23-25]. The 
incidence of SAB has been assessed in a number of population-based studies [18, 26-44], but 
national studies only exist from Denmark and Finland [26, 29, 31, 35, 38]. The incidence in 
adults has been reported to be 16-41 /100,000 person-years [18, 26-44]. The paediatric 
incidence has seldom been reported, but has been found to be 6.5-17 /100,000 child-years 
[26, 27, 35-37]. The risk of getting SAB increases with age and it is less common in children 
than in adults. Infants and neonates are, however, most commonly affected among children 
[21, 26, 29, 30, 35, 36]. The temporal changes in the epidemiology of SAB have been 
assessed by some researchers [21, 26, 28-31, 33-35, 38, 44]. A selection of important 
population-based studies on SAB is shown in Table 1.  
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Table 1. Selected population-based studies on S. aureus bacteraemia    
          
First author Population, years N Total 
incidence 
 /100,000 
Adult 
incidence 
 /100,000 
Paediatric 
incidence 
 /100,000 
Mortality  
 
%
a
 
Nosocomial 
acquisition 
% 
MRSA 
 
% 
Change in 
incidence 
over time 
All ages          
Lyytikainen [26] Finland, 1995-2001 5,045 14 16 6 (<15 y) 17 (children 1%) 51 <1 ↑ 55% 
Huggan [27] New Zealand, 1998-2006 779 21 24 13 (<15 y) 18
b 
(children 3%) 36 (51% HCA) 0.4 Fluctuating 
Laupland [28] Canada, 2000-06 1,542 20 NA NA 25 39 (36% HCA) 11 Stable 
Mejer [29] Denmark, 1995-2008 16,330 23 NA NA 26 57 0.8 Stable 
Laupland [30] 5 countries, 2000-08 18,430 26 NA NA NA 39 7 Stable 
Adult SAB         
Benfield [31] Denmark, 1981-2000 18,702 - 18-31 - 22-35 57 0.3 ↑ 68% 
Hill [32] New Zealand, 1996-97 424 - 41 - 19 50 5 - 
Allard [33] Canada, 1997-2005 ~368
c
 - 28  - 24 60 (26% HCA) 8 ↑ 34% 
El Atrouni [34] USA, 1998-2005 247 - 38 - NA 23 (59% HCA) 32 Stable 
Paper I Iceland, 1995-2008 721 21.5
d
 24.5 - 17
e
 46 (15% HCA) 0.6 ↑ 27% 
Paediatric SAB         
Frederiksen [35] Denmark, 1971-2000 2,648 - - 8.4 (<21 y) 2.5 55 0.5
f
 ↑ 83% 
Hill [36] New Zealand, 1996-98 125 - - 16.9 (<15 y) 3.1 30 6 - 
Vanderkooi [37] Canada, 2000-06 120 - - 6.5 (<18 y) 2.5 27 (18% HCA) 0.8 Stable 
Paper II Iceland, 1995-2011 146 21.5
d
 - 10.9 (<18 y) 1.4
g
 34 (14% HCA) 0 ↓ 36% 
N: number of SAB cases, MRSA: methicillin-resistant S. aureus, y: years, HCA: health-care associated, NA: not available, SAB: S. aureus bacteraemia. 
a. Mortality at one month or during admission.       
b. 30% 1-year mortality.      
c. Mortality and mode of acquisition based on 815 cases during 1991-2005.     
d. The combined incidence of adults and children during 1995-2008.     
e. 33% 1-year mortality.         
f. Rate in 1996-2000.         
g. 3.6% 1-year mortality.         
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1.4.2 Mode of acquisition 
A large proportion of SAB is acquired in a health-care setting. Usually 40-60% of adult cases 
in population-based studies have been found to be nosocomial, or hospital acquired [26-34], 
with even higher rates (50-70%) in institution-based reports [45-47]. Similar proportions have 
been seen in children, with 30-70% of SAB being nosocomial [21, 29, 35-37, 47-49]. SAB 
with an onset in the community can, however, be health-care associated if it is acquired in 
association with a health-care contact. Examples of this are individuals with chronic 
underlying diseases with frequent health-care contacts, and patients recently undergoing 
invasive procedures. Community-onset health-care associated bacteraemia has become 
regarded as a distinct entity, thought to share more similarities with nosocomial than with true 
community acquired infections regarding the antimicrobial susceptibility pattern of the 
pathogens and outcome [50-52]. Only a few studies on SAB have specifically identified this 
group of patients, and they have used somewhat different definitions. In adults, rates of 25-
60% have been reported [28, 33, 34, 53], and in children 15-35% [37, 47, 54]. 
 
1.4.3 Focus 
The most common focus, or source, of SAB has generally been reported to be skin and soft 
tissue infections and intravascular catheters. In a significant proportion of cases (10-40%) the 
focus cannot, however, be identified [31, 45, 53, 55]. Infective endocarditis (IE) is a serious 
complication or manifestation of SAB. Usually less than 15% of SAB patients are diagnosed 
with IE [31, 33, 45, 53, 56-58]. In a retrospective study on the treatment of Icelandic adults 
with SAB we found that only 3% (8/279) had an IE (echocardiography was performed in 
51% of episodes) [53]. The frequency of IE diagnosed is, however, linked to how frequently 
echocardiographies are performed. By actively performing echocardiography up to 30% of 
adults with SAB have been found to have IE [59-61]. Some therefore recommend that all 
patients with SAB should undergo echocardiography [61, 62]. IE is, however, rare in 
children, where <5% of SAB cases usually are reported to have IE [35, 37, 63], although 
higher rates have been reported [64]. 
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1.5 INFECTIVE ENDOCARDITIS 
1.5.1 History and incidence 
IE is a well-known disease since more than a century. Sir William Osler in 1885 held lectures 
on what he termed malignant endocarditis for the Royal College of Physicians of London 
where he gave a comprehensive overview of the disease [65]. Historically viridans 
streptococci were the most common cause of IE, but S. aureus today has become the leading 
causes of IE in many regions of the world. S. aureus accounts for 15-40% of all IE cases [66-
72], and approximately two thirds of cases in people who inject drugs (PWID) [66, 69, 73]. 
Population-based studies focusing on all IE cases have generally reported S. aureus 
endocarditis (SAE) rates of 0.2-1.6 /100,000 person-years [68, 70, 74, 75]. In a recent study 
performed in 7 regions of France the annual incidence of SAE was 0.90 /100,000 adults, and 
in an Italian region 0.76 /100,000 [70, 75]. In an older Swedish study from Gothenburg 
performed in 1984-88 an SAE incidence of at least 1.4 /100,000 inhabitants per year was 
found [74]. 
 
1.5.2 Pathogenesis 
The cardiac valvular endothelium is normally resistant to attachment and colonisation by 
bacteria. Damage to the endothelium can be caused by turbulent blood flow (from a 
congenital or acquired cardiac abnormality), repeated intravenous injections of solid particles 
(such as in intravenous drug users), or injury caused by intracardiac electrodes and catheters. 
Endothelial damage triggers blood coagulation with deposition of fibrin and platelets to form 
a sterile thrombus. Circulating microorganisms may adhere to the damaged endothelium, and 
subsequently proliferate and infect the valves. The bacteria become encased in the 
platelet/fibrin matrix, the infected coagulum is termed a vegetation. Absence of valve 
vasculature causes low penetration of phagocytic leukocytes into the infected tissue and the 
host immune response has difficulties fighting back the infection [76-78]. 
The mitral valve is most commonly affected in IE, followed by the aortic valve. The right-
sided valves (tricuspid and pulmonic valves) are less commonly involved except in PWID. 
Pathogens can also adhere to the fibronectin and fibrinogen coated surfaces of prosthetic 
heart valves, or other prosthetic intracardiac materials such as pacemaker and implantable 
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cardioverter defibrillator (ICD) leads. Prosthetic valve endocarditis is a severe form of IE and 
is associated with poorer prognosis [66, 79].  
Embolisation of a vegetation is a well-known complication of IE. Vegetations on the right-
sided valves embolise to the pulmonary circulation, while left-sided vegetations embolise via 
the systemic circulation. This can cause septic embolies in virtually any organ. Embolies to 
the central nervous system (CNS) can cause severe events, such as ischemic infarction or 
intracranial bleeding [76, 77, 80]. The risk of CNS embolisation depends on the size and the 
location of the vegetation, large vegetations (>10-15 mm) and mitral valve location being 
associated with higher risk [81-85]. IE caused by S. aureus is also associated with a higher 
risk of embolic events than IE caused by most other pathogens [67, 82]. Other possible 
complications of IE are valvular dysfunction (e.g. perforation of a valve, rupture of chordae, 
valve obstruction, prosthetic valve dehiscence) leading to congestive heart failure, and 
intracardiac abscess formation possibly disrupting the heart’s electrical conduction system 
and causing arrhythmias [76, 77, 80]. 
 
1.5.3 Diagnosis 
The diagnosis of IE is based on microbiologic, echocardiographic, clinical and 
histopathologic findings. The diagnostic criteria currently most widely used are the modified 
Duke criteria (Table 2). These modifications of the original Duke criteria from 1994 were 
proposed in the year 2000, previously other criteria have been used [86, 87]. 
Transoesophageal echocardiography is generally more sensitive and specific than 
transthoracic echocardiography in the diagnosis of IE [88, 89]. 
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Table 2. The modified Duke criteria for infective endocarditis a  
  
Pathologic criteria  
 • Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that 
has embolised, or an intracardiac abscess specimen; or 
 • Pathologic lesions: vegetation or intracardiac abscess confirmed by histologic examination showing 
active endocarditis. 
 
Major criteria 
 • Blood culture positive for IE 
 Typical microorganisms consistent with IE from 2 separate blood cultures: 
  Viridans streptococci, Streptococcus bovis, HACEK group, Staphylococcus aureus; or  
  Community-acquired enterococci, in the absence of a primary focus; or 
 Microorganisms consistent with IE from persistently positive blood cultures, defined as follows: 
  At least 2 positive cultures of blood samples drawn >12 hours apart; or 
  All of 3 or a majority of  ≥ 4 separate cultures of blood (with first and last sample drawn at least 1 
hour apart); or 
 Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titre >1:800. 
 • Evidence of endocardial involvement 
 Echocardiogram positive for IE, defined as follows: 
  Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on 
implanted material in the absence of an alternative anatomic explanation; or 
  Abscess; or 
  New partial dehiscence of prosthetic valve; or 
 New valvular regurgitation. 
 
Minor criteria 
 • Predisposition: predisposing heart condition or injection drug use. 
 • Fever: temperature >38°C. 
 • Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, 
intracranial haemorrhage, conjunctival haemorrhages, and Janeway’s lesions. 
 • Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor. 
 • Microbiological evidence: positive blood culture but does not meet a major criterion as noted 
above
b
, or a serological evidence of active infection with organism consistent with IE. 
   
Definition of infective endocarditis  
 Definite IE: 
  1 pathologic criterion; or 
  2 major criteria; or 
  1 major criterion and 3 minor criteria; or 
  5 minor criteria. 
 Possible IE: 
  1 major criterion and 1 minor criterion; or 
  3 minor criteria. 
 Rejected: 
  Firm alternate diagnosis explaining evidence of IE; or 
  Resolution of IE syndrome with antibiotic therapy for ≤ 4 days; or 
  No pathologic evidence of IE at surgery or autopsy, with antibiotic therapy for ≤ 4 days; or 
  Does not meet criteria for possible IE. 
IE: infective endocarditis, HACEK: Haemophilus spp, Actinobacillus actinomycetemcomitans, Cardiobacterium 
hominis, Eikenella corrodens, Kingella kingae. 
a. Based on Li, et al. [86]. 
b. Excludes single positive cultures for coagulase-negative staphylococci and organisms that do not cause IE. 
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1.6 OUTCOME OF S. AUREUS BACTERAEMIA AND ENDOCARDITIS 
In the pre-antibiotic area SAB carried a mortality of over 80% [3]. Today, the case fatality 
ratio at one month is generally 15-25% among adults in developed countries, although rates 
of up to 40% are occasionally reported [26-29, 31-33, 45, 46, 90-94]. In children it is 
considerably lower, 1-9% [26, 27, 29, 35-37, 48, 49, 54, 95] (Table 1). Long-term mortality 
associated with SAB, is either due to sequelae or complications caused by the SAB, or it 
reflects deaths from underlying diseases. It has, however, rarely been assessed [27, 46, 96, 
97]. Most of the studies on outcome in SAB have been institution-based rather than 
population-based. Increasing age is the most consistent and strongest predictor of mortality 
associated with SAB. Examples of other factors that have been associated with a detrimental 
outcome are presence of co-morbidities, antibiotic resistant S. aureus isolates, nosocomial 
acquisition, female sex, type and timing of the antibiotic treatment, presence of concomitant 
S. aureus bacteriuria, and having endocarditis as the source of bacteraemia [28, 53, 57, 63, 
90, 98, 99]. 
SAE is associated with worse outcome than IE caused by most other bacterial pathogens 
[100]. SAE is generally associated with 20-30% in-hospital mortality [67, 100-110]. Left-
sided disease is regarded to be more severe than right-sided [67, 100, 101]. A significant 
proportion of SAE patients (15-35%) experience symptomatic CNS complications, such as 
cerebral embolisation or CNS infection [67, 100-106, 108]. It should be realised that SAE is 
relatively infrequent in most institutions. Hence, previous studies on SAE have rarely 
included large number of patients [67, 100-108]. Of studies including more than 100 SAE 
episodes only one has focused exclusively on cases diagnosed in the 21
st
 century. This study 
included patients from 39 medical centres in 16 different countries during 2000-03 [100]. 
Single centre studies, on the other hand, often represent a more homogenous sample than 
multicentre studies, with less differences in data collection, diagnostics and treatment 
practices. A selection of large (≥ 100 cases) studies on SAE is shown in Table 3. 
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Table 3. Large studies on S. aureus endocarditis        
            
First author Location, years N IVDU 
 
% 
Right 
sided 
% 
Prosthetic 
valve 
% 
Nosocomial 
acquisition 
% 
MRSA 
 
% 
CNS 
events 
% 
Cardiac 
surgery 
% 
In-hospital 
mortality 
% 
One-year 
mortality 
% 
            
Fowler [100]  16 countries, 2000-03 558 21 NA 15 23 (HCA 16%) 27 21 38 22 NA 
Fernández 
Guerrero [101] 
Spain, 1985-2006 133 47 48 15 22 6 19 27 28 NA 
Hsu [102] Taiwan, 1995-2005 123 17 27 11 17 39 17 20 26 NA 
Remadi [103] France, 1991-2001 116 6 26 17 NA 13 28 47 26 37 
Miro [67] 5 countries, 1979-99 566
a
 37 44
b
 NA 24 15 21 26 20 NA 
Røder [104] Denmark, 1982-91 260
c
 (21)
d
 5 9 33 0 35 15
e
 46
e
 NA 
Watanakuna-
korn [105] 
USA, 1980-91 106 20 16 7 17 1 15 8 25 NA 
Espersen [106] Denmark, 1976-81 119
f
 9 12 3 38 0
g
 33 7
h
 35
h
 NA 
Cervera [107] Spain, 1995-2011 93
i
 12 (28)
j
 22 25 (HCA 9%) - 11 38 40 43 
Rasmussen 
[108] 
Denmark and Sweden, 
1996-2008 
170
k
 7 - 24 NA 2 41 41 22 39 
Paper III Sweden, 2004-13 245 49 37 11 9 (HCA 9%) 2 12 15 9 20 
N: number of SAE cases, IVDU: intravenous drug use, MRSA: methicillin-resistant S. aureus, CNS: central nervous system, NA: not available, HCA: health-care associated. 
a. Native valve S. aureus endocarditis only.    
b. Of 389 cases with echocardiographically defined vegetations.    
c. 177 (68%) cases clinically diagnosed, 83 (32%) not clinically suspected but autopsy confirmed.    
d. 103 of 485 suspected IE cases, but these were excluded from further analysis.    
e. Of 177 clinically diagnosed cases. ~62% mortality of all cases (including autopsy diagnosed).    
f. 54 (45%) cases clinically diagnosed, 65 (55%) not clinically suspected but autopsy confirmed.    
g. According to another publication by the same authors [111].    
h. Of 54 clinically diagnosed cases. 71% mortality of all cases (including autopsy diagnosed).    
i. Left-sided methicillin-sensitive S. aureus endocarditis only.    
j. 46 of 163 S. aureus endocarditis cases with available strains, but these were excluded from further analysis.    
k. Left-sided S. aureus endocarditis only.    
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1.7 ANTIBIOTIC TREATMENT OF SAB AND SAE 
S. aureus is naturally susceptible to most antibiotics. This susceptibility led to Sir Alexander 
Fleming’s discovery of penicillin in 1928 [112, 113]. S. aureus has, however, high ability to 
become antibiotic resistant. Within a few years from the introduction of penicillin in 1941 
resistance had become a significant problem, and today over 80% of S. aureus isolates are 
resistant to penicillin. Penicillin-resistance is generally caused by the bacterial production of 
beta-lactamases. In addition S. aureus early became able to develop resistance to other 
available antibiotics, such as erythromycin, streptomycin, and the tetracyclines [114-116]. 
Semi-synthetic penicillins (e.g. cloxacillin, nafcillin, and methicillin) are penicillinase-stable, 
and have for decades been the principal antibiotics used for the treatment of SAB. Other 
antibiotic classes such as the cephalosporins (e.g. cefazoline) and glycopeptides (e.g. 
vancomycin) have also been used [55, 113, 117]. Not long after the introduction of semi-
synthetic penicillins in the middle of the 20
th
 century, naturally occurring strains of 
methicillin-resistant S. aureus (MRSA) were reported [118]. Methicillin-resistance involves 
the expression of an acquired penicillin-binding protein (PBP2a) (encoded by the mecA 
gene), with reduced affinity to most betalactam antibiotics. Since then the prevalence of 
MRSA has steadily increased, with substantial regional differences [116, 119]. In the 
previously mentioned studies on SAB and SAE, MRSA rates of up to 40% have been 
observed [34, 102]. MRSA strains are most commonly seen in hospitals and other health-care 
facilities, but community acquired strains have been increasingly endemic in many parts of 
the world. Glycopeptides remain the most commonly used antibiotics for invasive MRSA 
infections, and resistance is still uncommon [62, 116, 119, 120]. 
Previously intravenous antibiotics for at least 4 weeks were generally recommended for 
treatment of SAB. Long treatment duration is thought to diminish the risk of relapses. 
Relapse rates of up to 18% are still being reported after SAB [53, 56, 121]. Today, 
intravenous treatment during 7-14 days is usually regarded as adequate for uncomplicated 
SAB. Two weeks intravenous duration has been recommended for right-sided endocarditis 
without any complications. At least 4 weeks intravenous treatment is often advocated for 
complicated SAB with metastatic infections, and 4-6 weeks for left-sided endocarditis [55, 
79, 80, 122-125]. In our previously mentioned study on the treatment of SAB in Icelandic 
adults, 47% (130/279) got substantially shorter intravenous treatment than the operating 
recommendations suggested [53]. In the case of prosthetic valve endocarditis a combination 
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antibiotic treatment with rifampicin is usually recommended for at least 4-6 weeks, adding 
gentamicin for the first 2 weeks. Rifampicin helps eradicate bacteria attached to foreign 
material [79, 80, 126]. Cardiac surgery may also be a necessary part of SAE treatment. 
 
1.8 CARDIAC SURGERY FOR S. AUREUS ENDOCARDITIS 
In previous reports on SAE valvular surgery has been performed in 20-45% of patients during 
the admission (early surgery) [67, 100-104, 107; 108] (Table 3). Indications for early surgery 
include heart failure (as a result of valve dysfunction), uncontrolled infection (e.g. 
intracardiac abscess formation, enlarging vegetation, persisting fever and positive blood 
cultures), and prevention of embolic events (e.g. large vegetations >10-15 mm, especially on 
the aortic or mitral valve). The decision regarding operation needs, however, to be 
individualised. The objectives of surgery are total removal of all infected tissue and 
reconstruction of cardiac morphology, accomplished with valve repair or valve replacement. 
Biological or mechanical prosthesis can be used [79, 89]. Early valvular surgery for SAE has 
by some been associated with lower in-hospital mortality [67], while others have failed to 
confirm such an association [100, 103]. The most common indication for late surgery (weeks 
to months after completion of the antibiotic treatment for IE) is valvular insufficiency causing 
heart failure [79].  
 
1.9 PEOPLE WHO INJECT DRUGS 
1.9.1 Infectious complications 
Intravenous drug use (IVDU) is a global health problem. The number of PWID in a given 
region is, however, difficult to estimate. In Stockholm County the number has been 
calculated to range from 1850 to 7800 [127-129] (National Board of Health and Welfare 
2014 (unpublished), Martin Kåberg, MD, personal communication). 
IVDU is associated with severe social problems as well as a wide range of medical 
complications. Infections are a major cause of morbidity and hospitalisation among PWID. 
These include infections caused by bacteria, fungi and viruses (e.g. HIV, and hepatitis C) 
[130, 131]. Skin- and soft tissue infections can result from unsterile injections, and are the 
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most common bacterial infections seen in PWID. Many microbes can be involved. S. aureus 
is the principal pathogen and it most often appears to originate from the drug user’s own skin 
and nose [130, 132]. S. aureus colonisation has been shown to be more common among 
PWID than in the general population [133]. PWID sustain considerable skin and mucosal 
damage, IVDU is often associated with poor hygiene, and the drugs injected can have both 
direct and indirect effects on the host immune response [134]. Transmission of S. aureus 
strains between individuals can occur within drug-use networks [135, 136]. If the bacteria 
gain access to the bloodstream this can result in IE, which is an important and serious reason 
for hospitalisation among PWID. Despite its importance, recent studies concerning SAE in 
PWID are few [100, 109, 137-141]. 
 
1.9.2 Incidence of endocarditis 
Reports on the incidence of IE among PWID are few and usually limited by small size or 
selected populations. An incidence of 3.3 /1,000 person-years among HIV-negative PWID 
(35 cases) and 13.8 among HIV-positive PWID (82 cases) was reported from Baltimore USA 
during 1988-98, where 76% of the 117 cases were caused by S. aureus [142]. In a smaller 
study from Amsterdam the IE incidence rates among HIV-negative (3 cases) and positive (14 
cases) PWID were 3.9 and 24.8 /1,000 person-years respectively during 1989-93. In this 
study 65% of the 17 cases were caused by S. aureus [143]. In the population-based study on 
IE in Gothenburg, Sweden, 7 IVDU-related IE cases were identified over a period of 5 years 
(1984-88) in an estimated population of 1280 PWID, hence the annual incidence was 1.1 
/1,000 person-years (all pathogens) [74]. Older reports have presented similar or lower 
estimates of the incidence [144, 145]. Thus, relatively little is known about the current 
epidemiology, clinical features, management and outcome of SAE in PWID.  
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2 AIMS 
 
The overall aims of this thesis were to assess the epidemiology, clinical aspects, and outcome 
of SAB and SAE in Iceland and Stockholm, respectively.  
 
More specifically the aims were as follows: 
1. To evaluate the incidence of SAB in adults in the Icelandic population, the 
associated short- and long-term fatality, and changes over time during 1995-
2008 (Paper I).  
2. To assess the incidence of SAB in Icelandic children, and the associated short- 
and long-term mortality during 1995-2011 (Paper II).  
3. To assess the proportions of nosocomial and health-care associated SAB in 
adults and children, and the isolates’ antimicrobial susceptibility (Paper I and 
II). 
4. To define the focus of SAB in children (Paper II).  
5. To evaluate the short- and long-term outcome, treatment, and clinical 
characteristics of SAE patients, and changes in incidence over time in 
Stockholm, Sweden, during 2004-2013 (Paper III).  
6. To study factors associated with valvular heart surgery and risk factors for 
mortality and CNS complications associated with SAE (Paper III). 
7. To study the incidence and associated short- and long-term mortality of SAE 
in PWID in Stockholm, Sweden, during 2004-2013 (Paper IV).  
8. To evaluate the clinical aspects and management of SAE in PWID, and 
compare with that in non-addicts (Paper IV). 
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3 MATERIALS AND METHODS 
 
3.1 PAPER I AND II – S. AUREUS BACTERAEMIA 
3.1.1 Study population 
In Iceland a university hospital is located in the capital, Reykjavik, and a teaching hospital in 
the town of Akureyri. Both hospitals include a clinical microbiological laboratory and 
paediatric departments. Smaller regional hospitals send blood cultures to either of two 
laboratories.  
At the end of the study period for adults (Dec 31
st
 2008) the Icelandic population ≥ 18 years 
of age consisted of 238,587 adults. During the period the proportion of persons ≥ 50 years of 
age rose from 33% to 38% of the adult population. At the end of the study period for children 
(Dec 31
st
 2011) the Icelandic population <18 years of age consisted of 79,851 children.  
 
3.1.2 Study protocol 
SAB cases occurring between January 1
st
 1995 and December 31
st
 2011 were retrospectively 
identified at the clinical microbiological laboratories. Adults ≥ 18 years of age with growth of 
S. aureus in a blood culture during 1995-2008 were included in Paper I. Children <18 years 
of age with a growth of S. aureus in a blood culture during 1995-2011 were included in Paper 
II. Information about admission and discharge dates, and microbiological data were obtained 
from medical records and from the laboratories. Clinical data were collected for the children 
and were obtained from medical records. Information about the national population and dates 
of death was available from Statistics Iceland. 
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3.1.3 Definitions 
3.1.3.1 SAB episode 
An episode of SAB was defined by the isolation of S. aureus from at least one blood culture 
bottle. All positive blood cultures in adults were considered to represent clinically significant 
SAB (Paper I). In children S. aureus was considered to be a contaminant and excluded if 
isolated from a single blood culture without a demonstrable source of infection and not 
judged as a being a true pathogen by the physicians treating the patient, and lacking event on 
follow up (Paper II). A new SAB episode was considered to be a relapse, and hence not 
counted as a separate episode, if it occurred within 90 days after the index bacteraemia. 
Blood culturing systems used at Landspitali University Hospital were BACTEC™ (Becton 
Dickinson and Company, Sparks, MD, USA) in 1995, Difco ESP® (Difco Laboratories, 
Detroit, MI, USA) in 1996-2002 and BacT/ALERT® (bioMérieux, Marcy l'Etoile, France) 
during 2002-11, and at Akureyri Hospital SEPTI-CHEK™ (Becton Dickinson and Company, 
Sparks, MD, USA) in 1995-99, Difco ESP® in 1999-2008 and BacT/ALERT® during 2008-
11. Antibiotic susceptibility testing was performed by disc diffusion tests according to the 
standards and definitions of the Clinical and Laboratory Standards Institute (CLSI). 
 
3.1.3.2 Mode of acquisition 
Nosocomial bacteraemia was defined as an episode for which the first positive blood culture 
was drawn more than two days after hospital admission. Positive culture drawn two days or 
less after hospital discharge with a minimum of two days stay was also defined as 
nosocomial. Infection occurring within the first 48 hours after birth was also classified as 
nosocomial.  
Health-care associated bacteraemia in adults (Paper I) was defined as an episode not being 
nosocomial but occurring in an individual who had been admitted to hospital for more than 
two days in the 90 days prior to bacteraemia. Health-care associated SAB in children (Paper 
II) was defined as one not being nosocomial but occurring in an individual having the 
following risk factors: 1) admittance to hospital for two or more days 90 days prior to the 
SAB, 2) attendance at a specialised hospital clinic or emergency department in the 30 days 
prior to SAB, 3) having an intravascular catheter at the time of infection, or 4) developing 
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SAB directly following a procedure in another health-care setting (modifications from 
Friedman et al.) [50].  
A community acquired bacteraemia was defined as one that was neither nosocomial nor 
health-care associated.  
 
3.1.3.3 SAB focus in children 
A local infection was considered to be the focus or source of SAB if localised symptoms or 
signs of infection were present at the time of bacteraemia as assessed by the treating 
physicians, often supported by microbiological and/or radiological findings, or if confirmed 
at autopsy.  
 
3.1.3.4 Mortality 
Thirty-day and 1-year mortality were defined as all-cause death within 30 and 365 days, 
respectively, from the SAB (Paper I and II). In children (Paper II) death was judged to be 
bacteraemia related if signs or symptoms due to SAB were persistent and/or if blood cultures 
were positive at the time of death, further if autopsy results confirmed S. aureus infection as 
the cause of death (modifications from Lodise et al.) [146].  
 
3.1.4 Statistical analysis 
The Pearson’s chi square test, or Fisher’s exact test when needed, was used for comparing 
categorical data. The Mann-Whitney U test was used to compare continuous data between 
two groups. Linear time trends in incidence and mortality rates were tested by the chi-squared 
trend test. Time trends in other data were evaluated by Kendall’s correlation. Survival data is 
displayed by Kaplan-Meier curves and groups were compared by the log-rank test. The level 
of significance was set at 0.05. For processing the data in Paper I the IBM
® 
SPSS
®
 Statistics 
17.0 program package was used. The data in Paper II were analysed with the JMP
®
 8.0.2 
statistical software from SAS Institute Inc (Cary, NC, USA). 
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3.1.5 Ethical permits 
Studies in Iceland were approved by the National Bioethics Committee and Data Protection 
Authority (VSNb2008030023/03-15 with an addition). 
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3.2 PAPER III AND IV – S. AUREUS ENDOCARDITIS 
3.2.1 Study population 
Stockholm County has some 2.2 million inhabitants (1.7 million adults ≥ 18 years). The 
number of PWID in the county has been estimated to be between 1850 and 7800, with an 
average of 4825 persons [127-129] (National Board of Health and Welfare 2014 
(unpublished), Martin Kåberg, MD, personal communication). The Karolinska University 
Hospital serves as a tertiary referral centre for the county’s entire population, providing 
secondary health-care to part of it. Patients with suspected or confirmed IE are usually 
admitted to specialised infectious diseases (ID) departments, although occasionally they may 
be treated by other medical specialities. The ID departments are also responsible for severely 
ill IE patients who require intensive care treatment, and patients who need valvular surgery 
are usually admitted to an ID department both before and after the operation. Approximately 
two thirds of ID in-patient beds and the only thoracic surgery department in the region are 
located at the Karolinska University Hospital. Hence, patients with suspected IE are often 
transferred to the hospital from smaller hospitals. Furthermore, most PWID needing 
admission for serious infections in Stockholm County are directly referred to and treated at a 
medical ward at the Karolinska University Hospital specialised for this purpose. Nearly all 
PWID with suspected SAE are therefore treated at our hospital. 
 
3.2.2 Study protocol 
Individuals treated for SAE at the Department of Infectious Diseases at Karolinska University 
Hospital between January 1
st
 2004 and December 31
st
 2013 were included. A retrospective 
search was done in the records of the department by diagnostic codes representing IE 
according to the 10
th
 revision of International Classification of Diseases (ICD-10). Clinical 
and microbiological data were obtained from medical records and patients with IE caused by 
S. aureus were identified. Patients with active IVDU were specifically identified. 
Echocardiography reports were reviewed and the diagnosis of IE was verified according to 
the modified Duke criteria [86].  
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3.2.3 Definitions 
3.2.3.1 SAE episode 
An episodes of IE was defined as definite or possible according to the modified Duke criteria 
(Table 2) [86, 87]. IE on pacemaker or ICD leads were considered to be definite if culture of 
removed leads demonstrated S. aureus or if the modified Duke criteria were fulfilled [147-
149]. IE was defined as right-sided if it only involved structures on the heart’s right side 
(tricuspid valve, pulmonic valve, pacemaker or ICD leads). IE was defined as left-sided if the 
aortic or mitral valves were engaged. SAE episodes involving both the right and left side 
were classified as left-sided. A new episode within 90 days after completing treatment for 
SAE was considered to be a relapse and not counted as a separate episode. The blood culture 
systems used at the Karolinska were BACTEC™ (Becton Dickinson and Company, Sparks, 
MD, USA) during 2004-07 and BacT/ALERT® (bioMérieux, Marcy l'Etoile, France) during 
2004-13. 
 
3.2.3.2 Mode of acquisition 
Nosocomial or hospital acquired SAE was defined if signs or symptoms of IE presented more 
than 48 hours after admission, or less than 48 hours after hospital discharge after a minimum 
of two days admission. Infection was also defined as nosocomial if it was related to 
haemodialysis. Other cases were considered to be community-onset episodes.  
Health-care associated community-onset SAE was considered if at least one of the following 
risk factors was present: 1) admittance to hospital for two or more days 90 days prior to the 
SAE, 2) attendance at a specialised hospital clinic or emergency department in the 30 days 
prior to SAE, 3) having an intravascular catheter at the time of infection, or 4) developing 
SAE directly following a procedure in another health-care setting [50].  
 
3.2.3.3 Underlying diseases and complications 
IVDU was judged to be active if there was a history of IVDU in the three years before the IE 
or if there was evidence of drug use in the year following the SAE. CNS involvement or 
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complication was defined as a CNS embolisation, intracranial haemorrhage, or CNS 
infection. Predisposing heart disease was defined as in the original Duke criteria [87, 150].  
 
3.2.3.4 Mortality 
In-hospital mortality was defined as all-cause death while still admitted to an acute care 
hospital, also if the patient had been transferred from the Karolinska University Hospital to 
another hospital and died there. Thirty-day and 1-year mortality were defined as all-cause 
death within 30 days and 365 days, respectively, from the SAE. 
 
3.2.4 Statistical analysis 
The Pearson’s chi square test, or Fisher’s exact test when needed, were used for comparing 
categorical data. The Mann-Whitney U test was used to compare continuous data. Time 
trends in incidence rates were tested by the chi-squared trend test. Survival data is displayed 
by Kaplan-Meier curves and groups were compared by the log-rank test. Multivariate logistic 
regression was performed to calculate the contribution of different variables to mortality, 
CNS complications and in-hospital cardiac surgery, with the likelihood ratio test being used. 
Variables were considered for the models in a stepwise fashion, but the final selection of 
variables was also based on clinical judgment. Level of significance was set at 0.05. For 
processing the data the JMP
®
 8.0.2 statistical software from SAS Institute Inc (Cary, NC, 
USA) was used.  
 
3.2.5 Ethical permits 
The studies were approved by the Ethical Review Board in Stockholm (2013/1069-31/2). 
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4 RESULTS AND DISCUSSIONS 
 
4.1 PAPER I AND II – S. AUREUS BACTERAEMIA 
Population-based studies have been proposed as the best way to assess the epidemiology of 
serious infectious diseases [23-25]. These two nationwide studies provide information on the 
epidemiology and outcome of adult and paediatric SAB in Iceland, and the changes over 
time. 
 
4.1.1 Patients 
In the study period 1995-2008 we identified 692 adults with 721 distinct episodes of SAB. 
Cases were identified from 19 hospitals and health-care institutions. The mean age at 
diagnosis was 62.6 years (range 18-99 years) and the male to female ratio was 1.4. During 
1995-2011 a total of 140 children had 146 distinct episodes of SAB. The median age at 
diagnosis was 7.4 years, and the male to female ratio 1.8. An additional 15 (9%) children 
were identified who had a positive blood culture result that was regarded as a contamination 
and therefore excluded. 
 
4.1.2 Incidence 
4.1.2.1 Incidence rates 
The incidence of SAB in Icelandic adults was 24.5 /100,000 person-years during 1995-2008, 
and the total (adult + paediatric) SAB incidence was 21.5 /100,000 person-years. Other 
population-based studies have reported incidence rates of 14 to 41 /100,000 person-years [18, 
26-34, 38-44], most of which have included children (Table 1). The incidence of paediatric 
SAB was 10.9 /100,000 child-years in 1995-2011. For boys it was 13.7 and for girls 7.9 
/100,000 (p=0.001). This is somewhat higher than found in other population-based studies on 
children [21, 26, 35, 40], although a similar or higher incidence has been reported earlier [27, 
36] (Table 1).  
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The differences seen in the incidence rates in studies from different countries and regions can 
have many possible explanations. Differences in population structures, such as age 
distribution and co-morbidities, play a role. Variations in health-care systems and diagnostic 
methods also can affect the observed incidence. Our blood culture sampling frequency during 
1995-2008 was similar to that reported from Finland during 1995-2001 [26]. Handling of 
contaminations differs between studies. Most of the adult population-based studies have 
included all positive blood cultures, and did not exclude suspected contaminations, while two 
of the population-based paediatric studies excluded probable contaminations from the 
analysis. In these 7-12% of blood cultures growing S. aureus were considered to be 
contaminations, compared to our 9% in Icelandic children [36, 40]. Finally, genetic and 
bacterial factors might possibly influence the incidence [8, 151, 152].  
In adults the incidence rate increased with age, whereas in children it was highest among the 
youngest. The incidence rate in infants (< 1 year) was similar to that for adults >55 years of 
age, but for children in general it was considerably lower than in adults (Figure 1). Others 
have reported similar dynamics in the age distribution of SAB [29, 30], and a high incidence 
in neonates and infants is consistent with previous reports on SAB and paediatric 
bloodstream infections in general [21, 22, 26, 29, 36, 37, 48]. Most of the infections in infants 
were nosocomial or health-care associated and occurred in vulnerable children. 
 
 
Figure 1. Age-specific incidence of paediatric and adult Staphylococcus aureus bacteraemia 
in Iceland during 1995-2008.  
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4.1.2.2 Changes in incidence in adults 
In adults the SAB incidence rate increased by 28%, from 22.3 /100,000 person-years in 1995-
99 to 28.8 in 2005-08 (p=0.01) (Table 4). A similar trend has been seen in two Nordic 
national studies and a Canadian study. In Denmark the incidence rose by 40% from 1981 to 
2000, in Finland by 55% from 1995 to 2001, and in Quebec, Canada by 34% from 1997 to 
2005 [26, 31, 33]. Other reports, including a recent multinational study have, however, found 
a stable incidence over time [29, 30, 34], and even a decrease has been reported [44] (Table 
1). 
The explanation for the increase in incidence is not clear. How frequently blood cultures are 
obtained might influence the observed incidence. The frequency of blood cultures analysed at 
the clinical microbiology laboratory at Landspitali University Hospital did not change 
substantially during the study period since it was 38.4 /1,000 adults per year in 1995-2001 
and 39.7 in 2002-08. As our definition of SAB episodes in adults included possible 
contaminations, any change in the rate of contaminations could be important. Such a change 
is unlikely since the percentage of SAB episodes with a single positive blood culture and the 
proportion with polymicrobial aetiology did not change significantly with time. The noted 
increase in SAB incidence thus seems to be a real increase. It might be attributed to an 
increase in predisposing risk factors for S. aureus infections, with an ageing population, with 
higher numbers of individuals living with malignancies, more people having chronic diseases 
such as diabetes and obesity, and expanding use of invasive procedures and prosthetic 
devices [153, 154].  
 
4.1.2.3 Changes in incidence in children 
The incidence of paediatric SAB decreased by 36% during 1995-2011, from 13.1 /100,000 
child-years in 1995-2003 to 8.4 in 2004-11 (p=0.001). A similar trend has not been observed 
in other studies on SAB in children. As opposed to this a stable or an increasing incidence of 
SAB has been described [35, 37]. A part of the explanation for the decreasing incidence could 
be the 27% reduction in the frequency of blood cultures collected in children during the 
period, from 19.6 /1,000 children per year during 1995-2003 to 14.3 /1,000 during 2004-11 
(p<0.001). The lower frequency of blood cultures towards the end of the study period can 
probably be attributed to an international financial crisis beginning in 2008. It hit Iceland hard 
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and a consequence of the crisis was that physicians were encouraged to reduce “unnecessary” 
investigations. This, however, does not explain a reduction that was observed prior to 2008. 
A factor leading to a real decrease in SAB incidence could be the extensive infection control 
measures that have been applied during the period possibly reducing the risk of S. aureus 
transmission. A strict national MRSA reduction policy has been in place from 2001 focusing 
on screening and isolation of at risk patients along with eradication of MRSA in positive 
individuals (“search and destroy” policy). Furthermore, a department of infection control was 
established in the university hospital in 2001, promoting for example improved intravascular 
catheter hygiene routines and starting a hand hygiene promotional campaign in 2004, 
emphasising the use of alcohol hand sanitisers [155].  
 
4.1.3 Mortality 
4.1.3.1 Short-term mortality 
The 30-day case fatality ratio among adults was 17.1% during 1995-2008, and the annual 
mortality rate (based on 30-day mortality) was calculated to be 4.3 deaths /100,000 adults. 
Towards the end of the study period the case fatality ratio had declined to 11.4% (in 2005-08) 
(Table 4). The 30-day mortality could, however, be an overestimate of mortality attributed to 
SAB since some patients most likely had serious underlying diseases and died of other 
causes. Our adult 30-day case fatality is relatively low in comparison to the 19-26% seen in 
most other population-based studies (Table 1) [26-28, 31-33]. Increasing age in adults was 
associated with higher 30-day mortality, the rate being 28% in persons ≥ 75 years of age. The 
mortality was 23% in nosocomial SAB, 15% in health-care associated SAB, and 10% in 
community acquired SAB (p<0.001). The mortality was similar among males (16%) and 
females (19%) (p=0.27). 
In children one death could be attributed to SAB (0.7%), and the 30-day mortality was 1.4% 
(2 deaths). This case fatality ratio is among the lowest reported in children. In the few other 
population-based studies the case fatality ratio has been some 1-3.5% [26, 27, 29, 35-37], 
while in institution-based studies 1.5-9% [47-49, 54, 95, 156]. The annual mortality rate 
(based on 30-day mortality) was calculated to be 0.15 deaths /100,000 children. 
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4.1.3.2 One-year mortality 
The 1-year case fatality ratio among adults was 33% during 1995-2008. This is relatively low 
compared to the 30-56% reported in previous studies [27, 46, 96, 97]. It was 41% for patients 
with nosocomial SAB, 36% in health-care associated SAB, and 22% in community-acquired 
infections (p<0.001). In Figure 2 the 1-year survival curves for the three different modes of 
acquisition (community acquired, health-care associated and nosocomial) are shown. Among 
patients who died within one year, 52% died during the first 30 days and 48% in the next 11 
months, which is very similar to the rates noted in two other studies [27, 46]. One-year 
mortality may reflect deaths from underlying co-morbid conditions as well as long-term 
sequelae of SAB. This illustrates that it may be important not only to look at the short-term 
mortality of adult patients with SAB. 
Table 4. Incidence and mortality of adult S. aureus bacteraemia in 
Iceland during three different time periods 
      
Variable 
 
1995-99 
(n = 216) 
2000-04 
(n = 242) 
2005-08 
(n = 263) 
p-
value 
Incidence rate, /105 person-years 22.4 23.1 28.9 .01 
 Age     
 18-34 years 3.4 6.7 8.5  
 35-54 years 12.3 13.9 15.4  
 55-74 years 55.7 43.3 51.1  
 ≥ 75 years 79.8 94.0 122.8  
 Mode of acquisition     
 Nosocomial 12.4 10.7 11.2 ns 
 Health care associated 3.5 3.0 4.3 ns 
 Community acquired 6.4 9.4 13.4 <.001 
Case fatality at 30 days, % 22.2 18.7 11.4 .001 
Case fatality at 1 year, % 38.9 32.8 28.2 .06 
Mortality rate, /105 person-yearsa 5.0 4.3 3.3 .048 
n: number of S. aureus bacteraemia episodes, ns: not significant. 
a. Mortality rate per population was calculated based on 30-day case fatality.  
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The 1-year mortality after SAB in children has to the authors’ knowledge never been assessed 
before. The 1-year mortality during 1995-2011 was 3.6%. The five children who died within 
one year all had nosocomial infections and serious underlying diseases, whereas no children 
with community-onset infections died (p=0.02). The difference between short- and long-term 
mortality in children thus primarily seems to reflect deaths from underlying co-morbid 
diseases rather than the SAB per se.  
 
 
 
Figure 2. One-year survival curves after adult S. aureus bacteraemia 
by different modes of acquisition (p<0.001, log-rank test). 
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4.1.3.3 Reasons for the low mortality in Iceland 
The reason for the low short- and long-term mortality among both our adults and children is 
not clear. It could in part reflect the low rate of antibiotic resistance. Low resistance rates 
generally make wider range of empiric antibiotic treatments effective, and SAB caused by 
MRSA has in some studies been associated with poor outcome compared to SAB caused by 
methicillin-sensitive S. aureus (MSSA) [28, 54, 99]. The relatively low proportion of 
nosocomial SAB in children could also play a role since nosocomial bacteraemia in some 
studies has been independently associated with a worse outcome [63, 99]. Furthermore, 
survival could possibly be related to local conditions, such as the quality of supportive care or 
the timing of diagnosis, or possibly to as yet unidentified bacterial or host factors [157, 158]. 
 
4.1.3.4 Changes in mortality over time 
The 30-day case fatality ratio associated with adult SAB decreased during the study period, 
from 22.2% in 1995-99 to 11.4% in 2005-08 (p=0.001), and the 1-year mortality from 38.9% 
to 28.2% (p=0.06) (Table 4). In Figure 3 the 1-year survival curves for different time periods 
are shown. Similarly, in-hospital mortality decreased in Denmark from 1981 to 2008 (by 37% 
during 1981-2000, and by 22% during 1995-2008), and in a Swiss study from 1980 to 2002 
(by 14%) [29, 31, 90], while other studies have not shown a change over time [26, 28]. The 
reason for the decreasing mortality in Iceland is not obvious. Similarly, a decreasing mortality 
associated with bloodstream infections in general was observed in the United States between 
1979 and 2000, and has in part been thought to reflect improvements in supportive treatment 
[159]. It may also be speculated that increased awareness and earlier diagnosis of bacteraemia 
and sepsis might have contributed, and possibly changes in bacterial factors. 
  
32 
 
 
Figure 3. One-year survival curves after adult S. aureus bacteraemia 
during three different time periods (p=0.03, log-rank test). 
 
 
4.1.4 Mode of acquisition 
In adult SAB 46% of cases were nosocomial, 15% health-care associated, and 39% 
community acquired. The proportion with nosocomial infections decreased during the period, 
from 56% in 1995-99 to 39% in 2005-08 (p=0.001), while community acquired SAB 
increased from 29% to 46% (p<0.001). In children 34% of episodes were nosocomial, 14% 
health-care associated, and 51% community acquired. Nosocomial and health-care associated 
infections were most common in the youngest children (Table 5). The percentage of 
nosocomial infections in our adults is in the same order as that reported in most other studies 
(Table 1) [26-28, 30, 32]. Among children the proportion is relatively low when compared to 
previous studies on paediatric SAB, which have generally found nosocomial infections to 
account for 30-70% of cases [21, 29, 35-37, 47-49]. This could in part be due to the 
population-based nature of our study, since it also included cases from smaller hospitals. It is 
  
 33 
 
also possible that the improved infection control measures undertaken after the year 2001 
mentioned previously could have contributed to a reduced risk for S. aureus transmission.  
A restricted definition for community-onset health-care associated SAB was used in adults 
since complete clinical information could not be collected for all patients. Therefore it is 
likely that the proportion of health-care associated SAB (15%) is an underestimation. SAB 
episodes in adult patients receiving ambulatory intravenous treatments or haemodialysis were 
considered to be health-care associated only if patients were admitted to a hospital in the 90 
days prior to the SAB. In children the definition of health-care associated infections was more 
complete. Considering the retrospective nature of the study it is nevertheless likely that some 
health-care associated paediatric cases have been unidentified. Our proportion (14%) of 
children with health-care associated infections might therefore also be an underestimation. 
Most studies on adult or paediatric SAB have not included health-care associated infections 
as a specific entity. Rates of 25-60% have, however, been reported in adults [28, 33, 34, 53], 
including our study for the period 2003-08 where more complete clinical data were collected 
(finding 27% health-care associated episodes) [53]. Two recent paediatric studies have 
reported figures similar to our findings in children [21, 54]. Our findings indicate that a 
significant proportion of community onset SAB in adults and children is health-care 
associated. Future studies should try to use well defined and consistent criteria when 
identifying health-care associated infections [160].  
 
4.1.5 Focus in children 
In our population-based study we found the most common focus for paediatric SAB to be 
bone and joint infections (40%), followed by intravascular catheters (30%), and an unknown 
focus (10%) (Table 5). This is very similar to the proportions reported from New Zealand, but 
differs from that found in a study from South-Africa [36, 54]. This is also somewhat different 
than what we found in 279 SAB episodes in Icelandic adults where the most common focus 
was intravascular catheters (21%), followed by unknown focus (20%), bone and joint 
infections (18%) and skin infections (15%) [53]. A marked difference was seen in the 
distribution of SAB foci between different age groups of children (Table 5). 
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Table 5. Comparison of paediatric S. aureus bacteraemia in different age groups 
 
Characteristics 
<1 year 
(n=44) 
1-5 years 
(n=24) 
6-17 years 
(n=78) 
Total 
(n=146) 
p-
valuea 
      
Male 29 (66) 16 (67) 49 (63) 94 (64) ns 
Mode of acquisition      
 Nosocomial 29 (66) 10 (42) 11 (14) 50 (34) <.001 
 Health-care associated 11 (25) 5 (21) 5 (6) 21 (14) .004 
 Community acquired 4 (9) 9 (38) 62 (79) 75 (51) <.001 
Infection focus      
 Bone and joint 2 (5) 5 (21) 52 (67) 59 (40) <.001 
 Intravascular catheter 22 (50) 12 (50) 10 (13) 44 (30) <.001 
 Skin and skin structure 3 (7) 1 (4) 6 (8) 10 (7) ns 
 Respiratory tract 3 (7) 4 (17) 2 (3) 9 (6) ns 
 Other b 6 (14) 0 (0) 3 (4) 9 (6) .047 
 Unknown c 8 (18) 2 (8) 5 (6) 15 (10) .04 
Outcome      
 Relapse 4 (9) 3 (13) 1 (1) 8 (5) .03 
 Mortality, SAB related 1 (2.3) 0 (0) 0 (0) 1 (0.7) ns 
 Mortality at 30 days 2 (4.6) 0 (0) 0 (0) 2 (1.4) ns 
 Mortality at 365 days d 4 (9.5) 1 (4.4) 0 (0) 5 (3.6) .007 
 
Data are number (%) of episodes.   
n: number of episodes, ns: not significant, SAB: S. aureus bacteraemia.  
a. p-values derived by comparing the groups <1 year and 6-17 years. 
b. Urinary tract infections (2), Parotitis (2), Endocarditis (1), Deep muscle abscess (1), Intra-abdominal 
infection (1), Endometritis in mother (1). 
c. Five of 15 had an intravascular catheter but no clear evidence of it being the source of bacteraemia 
(no local signs, symptoms nor positive culture). 
d. Excluding six re-infections from the analysis. 
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4.1.6 Antibiotic resistance 
Four (0.6%) cases of bacteraemia caused by MRSA were noted among our adults during 
1995-2008. They all survived. This figure is much lower than in most previous studies, but 
similar to that in the nationwide Finnish and Danish SAB studies [26, 31, 161]. No episode 
caused by MRSA was identified in children. In other studies the rate has varied from 0 to25% 
[21, 22, 35, 36, 47-49, 54, 95]. The most likely reason for the low frequency of MRSA is the 
strict policy against MRSA which has been implemented in hospitals in Iceland and in the 
other Nordic countries and the Netherlands [162, 163]. Since nosocomial SAB today often is 
regarded as being caused by MRSA, our results remind us that MSSA still is an important 
cause of nosocomial and health-care associated SAB.  
Eighteen percent of our SAB isolates obtained from adults were sensitive to penicillin, a 
percentage higher than that usually observed in S. aureus isolates [164, 165]. It is 
nevertheless close to the penicillin susceptibility of MSSA reported elsewhere [32, 117]. The 
17% penicillin susceptibility in children is higher than generally observed in paediatric SAB, 
also among MSSA isolates [36, 49, 54, 95]. Resistance to erythromycin and clindamycin 
were noted in 4% and 1%, respectively, in adults, and 3% and 2%, respectively, in children. 
Although an increasing level of resistance against clindamycin and erythromycin was 
observed in adults (Table I, Paper I), this level is still considerably lower than generally 
reported [32, 164, 165]. We found no correlation between the antibiotic susceptibility of our 
isolates and mortality.  
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4.2 PAPER III AND IV – S. AUREUS ENDOCARDITIS 
Earlier reports on SAE have rarely included many patients. These two studies from 
Stockholm describe a large number of individuals diagnosed with SAE during the past 
decade. Furthermore, since our hospital manages nearly all PWID with IE within a defined 
geographical area the results provide a fairly accurate overview of SAE in PWID on a 
population basis.  
 
4.2.1 Patients 
During 2004-13 a total of 245 SAE episodes were seen in 222 individuals, 227 (93%) were 
definite and 18 (7%) possible IE cases. Evidence of active IVDU was noted in 120 (49%) 
episodes in 101 individuals. An additional 6 episodes were seen in individuals with prior but 
not currently active IVDU. The valve involvement in our 245 SAE episodes is depicted in 
Table 6. This table further compares the valve involvement in PWID and non-addicts. 
Historically, IE associated with IVDU most often has been right-sided. We found that SAE 
related to IVDU was left-sided in 35%, which is consistent with a few other recent reports 
[100, 137, 139], but not all [101]. 
  
  
 37 
 
Table 6. Valve characteristics of 245 S. aureus endocarditis episodes 
       
Valve characteristics Total 
(n=245) 
 PWID 
(n=120) 
Non-addicts 
(n=125) 
p-
value 
      
Location      
 Left-sided a 152 (62)  42 (35) 110 (89) <.0001 
 Right-sided 91 (37)  77 (64) 14 (11) <.0001 
 Unknown 2 (1)  1 (1) 1 (1) ns 
Valve type b      
 Native 208 (85)  113 (94) 95 (76) <.0001 
 Prosthetic 28 (11)  7 (6) 21 (17) .007 
Number of valves involved c      
 One valve 193 (79)  86 (77) 107 (86) .01 
 Two valves 30 (12)  24 (21) 6 (5) .0003 
 Three valves 3 (1)  2 (2) 1 (1) ns 
Valves involved d      
 Aortic 79 (32)  20 (17) 59 (47) <.0001 
 Mitral 87 (36)  31 (26) 56 (45) .002 
 Tricuspid 87 (36)  82 (68) 5 (4) <.0001 
 Pulmonic 7 (3)  6 (5) 1 (1) .04 
 Pacemaker/ICD leads 13 (5)  (0) 13 (10) .0003 
 Other 1 (0.4)  0 (0) 1 (1) ns 
 Unknown 9 (4)  8 (7) 1 (1) .02 
       
Data are number (%) of episodes.  PWID: people who inject drugs, n: number of cases, ns: not 
significant, ICD: implantable cardioverter defibrillator. 
a. Including 19 cases with bilateral involvement. 
b. Thirteen pacemaker/ICD cases not shown. Each episode can involve >1 category. 
c. Unknown in 9 episodes, solely pacemaker/ICD leads in 10. 
d. Each episode can involve >1 category.
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4.2.2 Incidence 
4.2.2.1 Incidence rates 
We found a SAE incidence of 1.56 /100,000 person-years during 2004-13 in adults in 
Stockholm County. The incidence of IVDU-related SAE was 0.76 /100,000 person-years. 
SAE in Stockholm may also be treated in smaller hospitals and occasionally by other medical 
specialities outside the ID Department at Karolinska University Hospital. It is, however, 
unlikely that many IVDU-related cases were missed because of this. In addition some IE 
cases may not have received a correct diagnostic code and might thus have been missed. 
Hence, the total SAE incidence rate presented is probably lower than the actual incidence. 
The noted incidence, however, is among the highest reported, since previous population-
based studies on IE have generally reported rates of 0.2-1.6 /100,000 person-years [68, 70, 
74, 75]. Our incidence of IVDU-related SAE is very high when compared to the 
aforementioned studies, which generally included few IVDU-related cases (0-7% of IE 
episodes) [68, 70, 74, 75].  
The high SAE incidence found is probably in part due to the mostly urban population in 
Stockholm, leading to a high number of IVDU-related cases. Other population factors, such 
as variations in age distribution and co-morbidities, could also lead to differences between 
studies. As the diagnosis of IE is dependent on echocardiography and blood cultures, the 
incidence of SAE is related to how frequently these investigations are done. Thus the noted 
incidence could in part reflect a liberal use of diagnostic procedures and a high awareness 
among the medical personnel, in part due to the concentration of PWID to our hospital.  
 
4.2.2.2 Changes in incidence over time 
The incidence of SAE among adults in Stockholm County increased by 42% between the 
periods 2004-08 and 2009-13, from 1.28 to 1.82 /100,000 person-years (p=0.007). The 
incidence of SAE related to IVDU increased by 90% between the same time periods, from 
0.52 to 0.99 /100,000 (p=0.0001), and accounted for most of the increase. Figure 4 depicts 
the incidence of SAE in Stockholm in two-year intervals. Changes in the observed incidence 
might reflect a change in referral practices. However, such a change is an unlikely 
explanation. Our hospital has treated the majority of IE patients in Stockholm during the 
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entire period, and 46% were referred from other hospitals during 2009-13 compared to 51% 
during 2004-08 (p=0.41). The increased incidence could in part be due to an ageing 
population with more co-morbidities, and an increasing number of PWID. In Sweden a 
constant increase in the number of people with heavy narcotic use was seen from 1979 to 
2007 on a national level, with a 13% increase being noted between 1998 and 2007 [128]. 
Although no exact data on the prevalence of IVDU are available specifically for Stockholm 
County, the number of PWID in Stockholm has most likely also increased. An increasing 
number of PWID is, however, probably not the only explanation for the increased incidence 
of SAE related to IVDU. A marked increase in hospitalisations for IE associated to IVDU has 
also been reported from the United States while the at-risk population did not change [166]. 
Certain drugs have been claimed to be associated with higher risk to develop IE than others 
[166-168]. No change, however, was noted in the type of narcotic drugs used during the study 
period. Injection frequency probably also plays a role, but could not be assessed. Finally, a 
greater awareness of IE and better or more frequent utilisation of diagnostic procedures could 
result in an increase in the observed incidence. 
 
Figure 4. Incidence of S aureus endocarditis in Stockholm County by study years, 
intravenous drug use (IVDU) related (red) and total rate (blue). 
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4.2.2.3 Incidence in PWID 
It is not easy to estimate the incidence of SAE in PWID, since the exact number of drug users 
in a geographical region is usually unknown. We estimated that the SAE incidence in PWID 
in Stockholm was 2.5 (range 1.5-6.5) per 1,000 person-years. The range is quite wide due to 
the uncertainty of the exact number of PWID in the county. Two previous studies have 
reported a similar incidence of IE among HIV negative PWID, with higher rates in HIV 
positive PWID [142, 143]. Others have presented somewhat lower estimates [74, 144, 145].  
 
4.2.3 Characteristics 
4.2.3.1 Valve location and IVDU 
Characteristics of the 245 SAE cases are depicted in Table 7, with comparison between right- 
and left-sided episodes. Of our 91 cases with a right-sided SAE, 85% were seen in patients 
with active IVDU, and 12% were related to a pacemaker/ICD. PWID with left-sided SAE 
were older and more often had predisposing heart diseases than PWID with right-sided 
disease. Non-addicts with left-sided SAE were in turn generally older and more often had 
underlying diseases than PWID with left-sided SAE (Table II, Paper IV). 
  
  
 41 
 
Table 7. Characteristics of S. aureus endocarditis by location 
      
Characteristics Left-sided 
(n=152) 
Right-sided 
(n=91) 
p-
value 
Total 
(n=245) 
     
Age, median years 60.3 38.0 <.0001 53.4 
Male sex 117 (77) 54 (59) .004 173 (71) 
Underlying conditions     
 Intravenous drug use 42 (28) 77 (85) <.0001 120 (49) 
 Predisposing heart disease a 56 (37) 6 (7) <.0001 62 (25) 
Treatment     
 In-hospital cardiac surgery 37 (24) 0 (0) <.0001 37 (15) 
 Days of IV treatment, median b 34 29 .0001 32 
 Days admitted, median c 36 30 .003 33 
Outcome     
 ICU-admission, non post-op 34 (22) 17 (19) ns 51 (21) 
 Relapse of SAB d 2 (1) 5 (6) ns 7 (3) 
 30-day mortality 13 (9) 2 (2) .046 15 (6) 
 In-hospital mortality 20 (13) 2 (2) .004 22 (9) 
 1-year mortality e 40 (28) 6 (7) .0001 46 (20) 
        
Data are number (%) of episodes unless otherwise indicated. 
n: number of episodes, IV: intravenous, ICU: intensive care unit, ns: not significant, SAB: S. 
aureus bacteraemia. 
a. Prosthetic valve, congenital malformations (excluding atrial septal defect), valvular 
dysfunction, hypertrophic cardiomyopathy. 
b. Excluding 27 episodes: 22 deaths or end-of-life decisions while being treated, 5 lacking 
information.
 
c. Information missing in 11 transferred cases.
 
d. Excluding 15 patients who died within 30 days.
 
e. Excluding 8 cases with a re-infection within one year, 3 with incomplete follow-up. 
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4.2.3.2 Mode of acquisition 
Nosocomial SAE episodes accounted for 9.4% of cases, and an additional 9.4% were related 
to health-care without being nosocomial. This is considerably lower than the 17-38% 
nosocomial episodes found in most other studies (Table 3) [67, 100-102, 104-107]. The 
reason for the low proportion of nosocomial infections is in part due to the high percentage of 
PWID in our material. We only searched for SAE cases at the ID department and did not 
include cases treated by other medical specialities, which could also have influenced our 
findings. MRSA was seen in 6 (2%) SAE episodes, one was nosocomial and five were 
community acquired. The proportion of MRSA strains has varied greatly (0-40%) in earlier 
studies from different regions [67, 100-105, 108, 110]. 
 
4.2.3.3 Underlying diseases in PWID and drugs used 
Amphetamine was by 47% of the PWID reported to be the main injected drug used, followed 
by heroine by 43%. No correlation was seen between type of drug used and age, sex, valve 
involvement, surgical treatment or outcome. A HIV infection was seen in 10% of PWID, 
three individuals had CD4 counts <200 cells/mm
3
. Hepatitis C virus (HCV) infection was 
present in 82% of the PWID, 23% had both HCV and hepatitis B virus (HBV), and 3% HBV 
only. The proportion of different narcotic drugs injected, the male to female ratio, and the 
percentage of individuals infected with HCV, HBV and HIV in our study was similar to that 
reported from the county and noted in the Stockholm needle exchange program [127, 169]. 
Our patients with SAE related to IVDU thus seem to be representative for PWID generally 
seen in Stockholm. 
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4.2.4 Mortality 
4.2.4.1 SAE 
The 30-day mortality rate was 6.1% and 9.0% died during the acute hospitalisation. This case 
fatality is one of the lowest ever reported in association with SAE. It is much lower than the 
in-hospital SAE mortality of 19-46% observed in previous large studies (Table 3) [67, 100-
109, 170]. It is even lower than the 15-25% usually reported in association with S. aureus 
bacteraemia in general [26-28, 31-33, 94]. This is interesting since SAE is considered to be 
one of the most severe complications of SAB. More specifically the fatality was 13% in left-
sided SAE and 2% in right-sided SAE (p=0.004). For those who died during the admission, 
the median time to death was 25.5 days (range 5-61 days) implicating that most patients 
survived the acute phase, but died from complications later. The 1-year mortality was 19.7%, 
which is in the same order as that reported from Finland during 1980-2004 [170], but 
considerably lower than the 35-44% reported by others [103, 107, 108, 110, 171].  
 
4.2.4.2 SAE related to IVDU 
In PWID the 30-day and in-hospital mortality was 2.5%, the same for right- and left-sided 
SAE. This is lower than the 8-12% found in most previous reports [100, 101, 109, 138, 139], 
but a similar mortality was, however, noted in two older studies [140, 141]. At 1-year the 
mortality rate in our PWID was 8.0%, 4.1% in right-sided and 15.4% in left-sided SAE. Even 
if the mortality was low, almost one quarter (23%) needed intensive care treatment. PWID 
with left-sided SAE had a lower short- and long-term mortality than non-addicts (Table II, 
Paper IV), but PWID was not independently associated with mortality. The low mortality in 
PWID compared to that noted in non-addicts, can in part be explained by their lower age, the 
lower frequency of nosocomial infections, and the lack of major co-morbidities besides the 
IVDU. It has also been reported that PWID with SAB have a more vigorous antibody 
response to many S. aureus antigens than non-addicts, probably due to previous exposure to 
the infecting strain, and that this might offer some protection and contribute to the more 
favourable outcome [172]. Finally, transmission of S. aureus strains can occur within drug-
use networks [135, 136], and PWID with SAE might thus be colonised and infected with S. 
aureus strains associated with low mortality. A study looking at microbiological factors in 
SAE among PWID, however, did not find such an association [173]. 
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4.2.4.3 Reasons for the low mortality in Stockholm 
The reason for the low case fatality ratio associated with SAE in Stockholm is not clear. A 
high proportion of episodes related to IVDU probably has contributed. However, the 
mortality rates in non-addicts and in left-sided SAE were also lower than those generally 
seen. Referral bias is not likely to have had a major influence on the case fatality rate in our 
study. The low proportion of nosocomial and health-care associated cases could have 
contributed to the low mortality, since nosocomial IE by some has been associated with a 
worse outcome than community acquired [100, 174]. The low rate of MRSA might also have 
had an effect since MRSA bacteraemia sometimes has been associated with a higher 
mortality rate than bacteraemia caused by MSSA [63, 99]. A high awareness of IE among the 
medical doctors in Stockholm could have resulted in that more early and mild cases were 
diagnosed causing a lower mortality in our series. Also, differences in treatment practices [53, 
63] or bacterial and host genetic factors might possibly have contributed [157, 158, 175].  
 
4.2.4.4 Predictors of mortality 
Factors independently associated with in-hospital mortality were higher age (OR 1.06 per 
year) and female sex (OR 3.0) (Table 8). At one year, independent risk factors associated 
with mortality were higher age (OR 1.04 per year) and left-sided SAE (OR 2.7). Figure 5 
shows survival curves after SAE according to age. We have no explanations for the 
difference in mortality between the sexes, but a similar trend has occasionally been seen 
before in both SAE and in SAB [27, 29, 33, 63, 105]. It has been speculated whether 
differences in health-seeking behaviours between the genders and hormonal factors could 
play a role [29, 33, 63, 105]. Absence of surgical treatment was not associated with short- or 
long-term mortality. In one study a low frequency of cardiac surgery was independently 
associated with in-hospital mortality [67], while others have failed to find such an association 
[100, 103]. No difference was seen over time in the short- or long-term mortality rates. 
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Table 8. Factors associated with in-hospital mortality in S. aureus endocarditis 
           
  Univariate analysis  Multivariate analysis 
       
Variable Died 
(n=22) 
Survived 
(n=223) 
p-
value  
Odds ratio 
(95% CI) a 
p-
value 
       
Age, median years (IQR)  66 (56-85) 51 (35-67) <.0001  1.06 (1.02-1.09) b .0005 
Female sex 9 (41) 63 (28) .21  2.95 (1.06-8.16) .04 
Prosthetic valve IE 5 (23) 23 (10) .08  2.08 (0.59-6.48) .24 
Right-sided IE c 2 (9) 89 (40) .004  0.37 (0.05-1.60) .20 
In-hospital cardiac surgery 5 (23) 32 (14) .30  2.34 (0.62-8.12) .20 
        
Data are number (%) of episodes unless otherwise indicated. 
n: number of episodes in analysis, CI: confidence interval, IQR: interquartile range, IE: infective 
endocarditis. 
a. Odds ratios for the association between selected variables and in-hospital mortality in the multivariate 
analysis. Variables with odds ratios reported were included in the final multivariate logistic regression 
model. 
b. Odds ratio presented per one year increase in age. 
c. Unknown side in two episodes. 
 
 
Figure 5. Survival after S. aureus endocarditis according to age, < or ≥ 55 years (p<0.0001, 
log-rank test). 
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4.2.5 Central nervous system complications 
4.2.5.1 Rate of CNS involvement  
CNS involvement in association with the SAE was observed in 30 (12%) patients. Of these 6 
experienced an intracerebral bleeding and 2 had meningitis. The remainder had cerebral 
embolisation with neurological symptoms of various degrees. Our rate of CNS involvement 
is somewhat lower than 15-35% generally reported (Table 3) [67, 100, 101, 103, 105, 108]. 
We have already speculated that a high awareness of IE and early diagnosis could lead to low 
mortality. Diagnosis of more early and mild cases would probably also lead to fewer CNS 
complications being observed. 
 
4.2.5.2 Predictors of CNS involvement 
Factors independently associated with having a CNS involvement were lower age (OR 1.04 
per year), not being an intravenous-drug-user (OR 3.8), and mitral valve involvement (OR 
2.7) (Table 9). Mitral valve involvement has in previous studies on IE been found to be an 
independent predictor of CNS complications [81, 82]. Lower age has earlier been 
independently associated with increased risk of CNS events in IE in general, but the cause of 
this is not well understood [82, 83, 176]. It may, however, be that CNS events are simply 
under-diagnosed in the older population as a result of more unspecific symptoms and signs 
[82, 83, 176]. The reason for the independent association noted between IVDU and having a 
lower risk of CNS complications is unclear. Vegetation size has often been found to be a 
predictor of cerebral embolism [81-84]. This could, however, not be analysed due to 
inconsistent registration of vegetation size in our records. 
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Table 9. Factors associated with central nervous system involvement in left-sided 
S. aureus endocarditis 
          
  Univariate analysis  Multivariate analysis 
       
Variable CNS event 
(n=30) 
No CNS event 
(n=122) 
p-
value  
Odds ratio  
(95% CI) a 
p-
value 
       
Age, median years (IQR) 54 (43-68) 62 (51-75) .02  0.96 (0.93-0.99) b .007 
Mitral valve IE c 21 (70) 66 (54) .11  2.66 (1.06-7.28) .04 
Intravenous drug use 9 (30) 33 (27) .75  0.26 (0.07-0.86) .03 
Previous IE 8 (27) 16 (13) .07  3.21 (1.00-10.43) .05 
        
Data are number (%) of episodes unless otherwise indicated. 
CNS: central nervous system, n: number of episodes in analysis, CI: confidence interval, IQR: interquartile 
range, IE: infective endocarditis. 
a. Odds ratios for the association between selected variables and CNS involvement in the multivariate 
analysis. Variables with odds ratios reported were included in the final multivariate logistic regression 
model. 
b. Odds ratio presented per one year increase in age. 
c. Each episode may involve >1 valve. 
 
 
4.2.6 Treatment 
4.2.6.1 Cardiac surgery 
Cardiac surgery was performed before discharge in 15% of our SAE patients, all had a left-
sided SAE (24% operation frequency in left-sided SAE). This is lower than the 20-45% 
usually reported in association with SAE (Table 3) [67, 100-103, 107, 108], but similar or 
even lower rates have been reported during the 1980s [104, 105].  
Valvular surgery was performed during the hospitalisation in only 8% of PWID (24% of the 
left-sided, no right-sided), compared to 22% of non-addicts (p=0.004). This is lower than the 
35% observed by Fowler et al. but similar to the findings from older studies on PWID mostly 
from the 1980’s [100, 138-140]. Interestingly, the cardiac surgery was performed earlier in 
PWID than in non-addicts (6 days median time to operation compared to 11 days in non-
addicts, p=0.03). This indicates that PWID who were selected for surgery had a more 
advanced disease than non-addicts.  
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4.2.6.2 Predictors of cardiac surgery 
In left-sided IE lower age, no active IVDU, community onset infection, multi-valvular 
involvement, and ICU-admission were identified by multivariate logistic regression as 
independent predictors for cardiac surgery (Table 10). Higher age has earlier been associated 
with lower operation frequency in association with IE in general [176, 177]. Admission to 
ICU and multi-valvular involvement are both associated with the severity of IE [178, 179], 
old age and nosocomial infections are usually correlated with more co-morbidities, IVDU is a 
risk factor to acquire a new IE, and PWID are often regarded as less compliant to treatments. 
This might all influence the decision to perform surgery [180-182]. No difference was seen 
over time in the operation frequency. 
 
 
Table 10. Factors associated with early cardiac surgery for left-sided S. aureus 
endocarditis 
        
  Univariate analysis  Multivariate analysis 
       
Variable Operated 
(n=37) 
Not-operated 
(n=115) 
p-
value 
 Odds ratio 
(95% CI) a 
p-
value 
       
Age, median years (IQR)  53 (44-62) 64 (51-78) .0005  0.93 (0.89-0.97) b .0001 
Nosocomial IE 2 (5) 16 (14) .16  0.08 (0.01-0.44) .002 
Multivalvular IE 13 (35) 16 (14) .004  6.70 (1.80-30.23) .004 
Intravenous drug use 10 (27) 32 (28) .92  0.06 (0.01-0.25) <.0001 
ICU-admission, non post-op 16 (43) 18 (16) .0005  3.56 (1.37-9.45) .01 
 
Data are number (%) of episodes unless otherwise indicated. 
n: number of episodes in analysis, CI: confidence interval, IQR: interquartile range, IE: infective endocarditis, 
ICU: intensive care unit. 
a. Odds ratios for the association between selected variables and in-hospital surgery in the multivariate 
analysis. Variables with odds ratios reported were included in the final multivariate logistic regression model. 
b. Odds ratio presented per one year increase in age. 
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4.2.6.3 Antibiotic treatment 
Cloxacillin was the principal treatment in 76% of the cases, followed by cephalosporins 
(17%) and vancomycin (5%). This reflects the low rate of MRSA isolates. The median 
duration of intravenous treatment with antibiotics was 32 days. In 40 non-immune-
compromised patients with isolated uncomplicated right-sided SAE, without known septic 
emboli outside the lungs and no other deep focus or other complication, the median 
intravenous treatment duration was a full 29 days. The ID specialists in our institution thus do 
not seem to shorten the duration of antibiotic treatment in these cases, despite existing 
instructions and evidence which recommend this [79, 80, 183].  
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5 CONCLUSIONS 
 
The incidence of S. aureus bacteraemia and endocarditis 
In Iceland the incidence of SAB was similar to that in other regions, while the SAE incidence 
in Stockholm was high. Furthermore, an increasing incidence of adult SAB was noted during 
1995 to 2008 in Iceland, and of SAE during 2004 to 2013 in Stockholm. The increase in both 
regions was probably related to changes in risk factors both for SAB and SAE, such as an 
ageing population, more people living with chronic diseases, and a rising number of PWID. It 
might also be that more frequent utilisation of diagnostic procedures for IE has contributed.  
A decrease was, however, observed in the SAB incidence in Icelandic children from 1995 to 
2011. The decrease was probably in part due to a lower blood culture frequency attributed to 
savings inflicted by an international financial crisis starting in 2008, but infection control 
measures introduced during the period might also have reduced the S. aureus transmission 
rate. The paediatric SAB incidence was considerably lower than in adults, except for in 
infants and neonates.  
The SAE incidence in PWID in Stockholm was 2.5 per 1,000 person-years, which underlines 
the importance of SAE in this group. Compared to non-addicts, PWID had cardiac valvular 
surgery less commonly performed and a more favourable outcome.  
In adults almost half of SAB cases were nosocomial, and one-third of episodes in children. A 
decrease in the proportion of nosocomial infections was observed in adult SAB during 1995 
to 2008, possibly as a result of improved infection control measures. Health-care associated 
SAB and SAE were 15% and 9%, respectively. Hence, a significant proportion of 
community-onset SAB and SAE is health-care associated, a distinct entity which shares more 
similarities with nosocomial than true community acquired infections. The most common 
focus of SAB in children was bone and joint infections followed by intravascular catheters, 
which is somewhat different from that in adults. Very few MRSA isolates were seen in both 
Iceland and Stockholm, most likely a result of the strict MRSA reduction policies applied in 
both regions.  
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The mortality of S. aureus bacteraemia and endocarditis 
A reduction was seen in the case fatality ratio associated with SAB in adults in Iceland during 
1995 to 2008, to become one of the lowest reported. The case fatality noted in children was 
also among the lowest reported. The mortality associated with SAE in Stockholm was also 
very low compared to earlier studies, both in PWID and non-addicts, and CNS complications 
were less common. Relatively few patients needed valvular surgery for the SAE. The reason 
for the favourable outcome of SAB and SAE in Iceland and Stockholm, respectively, is not 
clear. Low rates of antibiotic resistance might have played a role. It could also be related to a 
high awareness and a more liberal utilisation of diagnostic procedures in these regions, 
leading to the diagnosis of more early and mild cases. Factors related to population 
demographics, co-morbidities, the treatment, or possibly unidentified bacterial or host genetic 
factors might also have contributed.  
The 1-year mortality rate in adult SAB and SAE increased with age, and was higher in 
nosocomial compared to community-onset SAB. The children who died within a year from 
the SAB all had nosocomial infections and serious underlying co-morbidities. The long-term 
mortality after SAB and SAE both reflects deaths associated with underlying diseases and 
from the infections per se. 
 
To conclude we found changing incidence rates over time but a favourable short- and long-
term outcome associated with SAB and SAE in Iceland and Stockholm.  
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